Reckitt Benckiser (OTCMKTS:RBGLY) has received an average rating of “Hold” from the eight analysts that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on th
Research firm Newzoo recently reported that five games dominated the U.S. PC market in April: Activision Blizzard's (NASDAQ:ATVI) Hearthstone and Overwatch, Tencent's (NASDAQOTH:TCEHY) League of Legends, Epic Games' Fortnite, and PUBG Corporation's PlayerUnknown's Battlegrounds(PUBG).
Pegasystems (NASDAQ:PEGA) is an online CRM (customer relationship manager) that must be doing something right because is up against a much bigger and formidable competitor like Salesforce (NYSE:CRM), as well as other much bigger companies like SAP AG (NYSE:SAP) and Oracle (NYSE:ORCL).
It can be instructive to look at the relative performance. First, the stock price development over the last....More>>>
Our Buyback Premium Portfolio is beating the S&P 500 by more than 97% since its inception in August of 2000; this portfolio is up 153.50% since inception vs. a gain of 55.69% in the S&P 500 over the same time frame, explains David Fried, editor of The Buyback Letter.
Sunnyvale, Calif.-based Rambus Inc. (RMBS) designs, develops, and licenses cutting-edge chip interface technologies....More>>>
How to play the turnaround in the Brazilian economy
Investing in emerging markets always has a heightened amount of risk associated with it. However, large and mid-cap stocks can help mitigate the heightened amount of risk. This is why I believe that the iShares MSCI Brazil Index (EWZ) is the safest way to play the turnaround in the Brazilian economy. The MSCI Brazil 25/50 Index is designed....More>>>
Related EWZ The Brazilian Giver: Maranh茫o Goes Back On Rousseff's Impeachment Annulment Rousseff Impeachment Vote Surprisingly Annulled Gold Shines A Light On Dollar Weakness (Seeking Alpha)
Related BRF The Brazilian Giver: Maranh茫o Goes Back On Rousseff's Impeachment Annulment Rousseff Impeachment....More>>>
Pasadena, CA, based Investment company Poplar Forest Capital LLC buys Signet Jewelers, Zimmer Biomet Holdings, Abbott Laboratories, St Jude Medical, Weatherford International PLC, Keysight Technologies, sells Intersil, Allstate, Lincoln National, Bank of Americaoration, Microsoft during the 3-months ended 2016-12-31, according to the most recent filings of the investment company, Poplar Forest Capital....More>>>
Following past boom/bust cycles, the oil business appears to have bottomed in February 2016 at $27 a barrel. The bruising multi-year bust in crude oil prices was the biggest reason for the world stock market sell-off from late 2015 to early 2016 of roughly 15% overall. The cruel irony of ultra-low prices is its disruptive effect on regular exploration activity. A short-term oil market depression....More>>>
Chesapeake Energy’s (NYSE:CHK) shares have fallen off of 52-week highs lately on the back of profit taking. However, recovering crude oil prices and Chesapeake Energy’s more aggressive capital program for 2017 suggest that the oil and natural gas company is much more optimistic about its future than it was just a short while ago. Further, after selling more than $2 billion in assets....More>>>
Last week, President Donald Trump's long-awaited speech on how he plans to rein in drug prices was delivered, and while he outlined some moves that could crimp drug costs, his plan didn't include giving Medicare widespread power to negotiate prices nor did it include a plan to allow drug reimpor
Bruker (NASDAQ:BRKR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The brokerage presently has a $34.00 price target on the medical research company’s stock. Zacks Investment Research‘s target
Intellia Therapeutics (NASDAQ: NTLA) and Meridian Bioscience (NASDAQ:VIVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valua
Oppenheimer set a $120.00 target price on Neurocrine Biosciences (NASDAQ:NBIX) in a report published on Monday morning. The brokerage currently has a buy rating on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ FY2021 earnings at $7.03 EPS and FY2022 earnings at